Latest Graft-versus-host disease Stories
Starting with a discovery in zebrafish in 2007, Harvard Stem Cell Institute (HSCI) researchers have published initial results of a Phase Ib human clinical trial of a therapeutic that has the potential to improve the success of blood stem cell transplantation.
Researchers from Indiana University, the University of Michigan, the Fred Hutchinson Cancer Research Center and the Dana-Farber Cancer Institute have identified and validated a biomarker accessible in blood tests that could be used to predict which stem cell transplant patients are at highest risk for a potentially fatal immune response called graft-versus-host disease.
Patients with advanced chronic lymphocytic leukemia (CLL) often receive donor transplants that effectively "reboot" their own immune defenses, which then attack and potentially cure the hard-to-treat disease.
- A gift; a largess; a gratuity; a present; a dole.